Jonathan Young Sells 2,503 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 2,503 shares of Akero Therapeutics stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $30.79, for a total value of $77,067.37. Following the completion of the transaction, the chief operating officer now owns 203,783 shares in the company, valued at $6,274,478.57. This represents a 1.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Jonathan Young also recently made the following trade(s):

• On Monday, December 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $32.13, for a total transaction of $321,300.00.
• On Friday, November 1st, Jonathan Young sold 50,716 shares of Akero Therapeutics stock. The shares were sold at an average price of $31.57, for a total value of $1,601,104.12.
• On Monday, October 14th, Jonathan Young sold 40,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.15, for a total transaction of $1,206,000.00.
• On Tuesday, October 1st, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $28.18, for a total value of $281,800.00.

Akero Therapeutics Stock Down 0.5 %

Shares of NASDAQ AKRO opened at $28.89 on Friday. The stock has a market cap of $2.02 billion, a PE ratio of -7.70 and a beta of -0.23. The company has a 50-day moving average of $30.81 and a 200 day moving average of $27.13. Akero Therapeutics, Inc. has a 12-month low of $15.32 and a 12-month high of $37.00. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings results on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.15). As a group, sell-side analysts predict that Akero Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Akero Therapeutics in a research report on Monday, November 18th. Citigroup assumed coverage on Akero Therapeutics in a research note on Monday, November 18th. They set a “buy” rating and a $65.00 target price for the company. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $46.83.

Institutional Investors Weigh In On Akero Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC lifted its position in Akero Therapeutics by 191.2% in the second quarter. SG Americas Securities LLC now owns 14,517 shares of the company’s stock valued at $341,000 after buying an additional 9,532 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Akero Therapeutics by 32.8% in the second quarter. Bank of New York Mellon Corp now owns 251,234 shares of the company’s stock worth $5,894,000 after acquiring an additional 61,988 shares in the last quarter. Rhumbline Advisers grew its stake in Akero Therapeutics by 30.3% during the 2nd quarter. Rhumbline Advisers now owns 107,338 shares of the company’s stock worth $2,518,000 after purchasing an additional 24,940 shares in the last quarter. TD Asset Management Inc increased its stake in shares of Akero Therapeutics by 23.7% during the second quarter. TD Asset Management Inc now owns 154,592 shares of the company’s stock worth $3,627,000 after buying an additional 29,600 shares during the period. Finally, Quest Partners LLC increased its position in shares of Akero Therapeutics by 22,021.1% in the 2nd quarter. Quest Partners LLC now owns 12,609 shares of the company’s stock valued at $296,000 after purchasing an additional 12,552 shares during the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.